JP2024511996A5 - - Google Patents

Info

Publication number
JP2024511996A5
JP2024511996A5 JP2023557285A JP2023557285A JP2024511996A5 JP 2024511996 A5 JP2024511996 A5 JP 2024511996A5 JP 2023557285 A JP2023557285 A JP 2023557285A JP 2023557285 A JP2023557285 A JP 2023557285A JP 2024511996 A5 JP2024511996 A5 JP 2024511996A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
alkyl
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020700 external-priority patent/WO2022197892A1/en
Publication of JP2024511996A publication Critical patent/JP2024511996A/ja
Publication of JP2024511996A5 publication Critical patent/JP2024511996A5/ja
Pending legal-status Critical Current

Links

JP2023557285A 2021-03-17 2022-03-17 抗がん剤としてのプリン誘導体 Pending JP2024511996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162460P 2021-03-17 2021-03-17
US63/162,460 2021-03-17
PCT/US2022/020700 WO2022197892A1 (en) 2021-03-17 2022-03-17 Purine derivatives as anticancer agents

Publications (2)

Publication Number Publication Date
JP2024511996A JP2024511996A (ja) 2024-03-18
JP2024511996A5 true JP2024511996A5 (cg-RX-API-DMAC7.html) 2025-03-26

Family

ID=81327909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557285A Pending JP2024511996A (ja) 2021-03-17 2022-03-17 抗がん剤としてのプリン誘導体

Country Status (11)

Country Link
US (1) US20240059689A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511996A (cg-RX-API-DMAC7.html)
KR (1) KR20240006509A (cg-RX-API-DMAC7.html)
CN (1) CN117425656A (cg-RX-API-DMAC7.html)
AU (1) AU2022238886A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018799A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212292A1 (cg-RX-API-DMAC7.html)
IL (1) IL305991A (cg-RX-API-DMAC7.html)
MX (1) MX2023010909A (cg-RX-API-DMAC7.html)
WO (1) WO2022197892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240190A (es) * 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos
KR20240117556A (ko) 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
EP4739397A1 (en) 2023-07-06 2026-05-13 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN117024253A (zh) * 2023-08-14 2023-11-10 江西阿尔法高科药业有限公司 一种药用级麝香草酚特定杂质的制备方法
AU2024378865A1 (en) 2023-11-10 2026-06-25 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025256544A1 (zh) * 2024-06-11 2025-12-18 福建盛迪医药有限公司 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法
CN119751316A (zh) * 2024-12-20 2025-04-04 江南大学 一种1-苯基三氟甲基n-(氟磺酰基)氨基甲酸酯化合物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2406129T3 (es) * 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
JP2011236198A (ja) * 2010-04-13 2011-11-24 Daiichi Sankyo Co Ltd モルホリノプリン誘導体
CN114702495A (zh) * 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
WO2020132269A1 (en) * 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors

Similar Documents

Publication Publication Date Title
JP2021534168A5 (cg-RX-API-DMAC7.html)
JP2022137047A5 (cg-RX-API-DMAC7.html)
HRP20201821T1 (hr) Inhibitori arginaze i njihove terapeutske primjene
RU2472797C2 (ru) ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
JP2015529235A5 (cg-RX-API-DMAC7.html)
CN110582483A (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JP2023515235A5 (cg-RX-API-DMAC7.html)
HRP20251115T1 (hr) Metode i spojevi za obnavljanje funkcije mutanta p53
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2023508357A (ja) エストロゲン受容体分解剤とサイクリン依存性キナーゼ阻害剤との癌治療用組み合わせ
JP2010516626A5 (cg-RX-API-DMAC7.html)
JP2014514317A5 (cg-RX-API-DMAC7.html)
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
CA3293479A1 (en) Bicyclic urea kinase inhibitors and uses thereof
JP2017128612A (ja) Arry−380の多形体、選択的erbb2(her2)阻害剤、およびそれらを含有する薬学的組成物
JP2015534975A5 (cg-RX-API-DMAC7.html)
JP2011511095A5 (cg-RX-API-DMAC7.html)
JP2019529444A5 (cg-RX-API-DMAC7.html)
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
JP2015536986A5 (cg-RX-API-DMAC7.html)
JP2023506787A5 (cg-RX-API-DMAC7.html)
JP2020504716A5 (cg-RX-API-DMAC7.html)
JP2025511122A5 (cg-RX-API-DMAC7.html)
JP2016508969A5 (cg-RX-API-DMAC7.html)
SG11202113307TA (en) Cot modulators and methods of use thereof